Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis
Authors
Keywords
Rheumatoid Arthritis, Rheumatoid Arthritis Patient, Herpes Zoster, Active Rheumatoid Arthritis, Tofacitinib
Journal
BIODRUGS
Volume 30, Issue 5, Pages 407-419
Publisher
Springer Nature
Online
2016-08-31
DOI
10.1007/s40259-016-0190-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study
- (2016) Y. Tanaka et al. JOURNAL OF RHEUMATOLOGY
- RA-BEACON illuminates baricitinib
- (2016) Dario Ummarino Nature Reviews Rheumatology
- Baricitinib in Patients with Refractory Rheumatoid Arthritis
- (2016) Mark C. Genovese et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of the Effect of Tofacitinib Exposure on Outcomes in Kidney Transplant Patients
- (2015) F. Vincenti et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
- (2015) Jeffrey R Curtis et al. ANNALS OF THE RHEUMATIC DISEASES
- Super-enhancers delineate disease-associated regulatory nodes in T cells
- (2015) Golnaz Vahedi et al. NATURE
- Amplification of IL-21 signalling pathway through Bruton’s tyrosine kinase in human B cell activation
- (2015) Sheau-Pey Wang et al. RHEUMATOLOGY
- The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
- (2014) D L Boyle et al. ANNALS OF THE RHEUMATIC DISEASES
- Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
- (2014) Edward C Keystone et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial
- (2014) Gerd-Rűdiger Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape
- (2014) Deepak Mittal et al. CURRENT OPINION IN IMMUNOLOGY
- Tofacitinib Suppresses Antibody Responses to Protein Therapeutics in Murine Hosts
- (2014) M. Onda et al. JOURNAL OF IMMUNOLOGY
- Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies
- (2014) J. Wollenhaupt et al. JOURNAL OF RHEUMATOLOGY
- Tofacitinib versus Methotrexate in Rheumatoid Arthritis
- (2014) Eun Bong Lee et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events
- (2014) Koshiro Sonomoto et al. RHEUMATOLOGY
- Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets
- (2014) D. E. Furst et al. RHEUMATOLOGY
- Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
- (2014) Kevin L. Winthrop et al. Arthritis & Rheumatology
- Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis
- (2013) Joel Kremer et al. ANNALS OF INTERNAL MEDICINE
- The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells
- (2013) Satoshi Kubo et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study
- (2013) Désirée van der Heijde et al. ARTHRITIS AND RHEUMATISM
- Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases
- (2013) L. Van Rompaey et al. JOURNAL OF IMMUNOLOGY
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
- (2013) Gerd R Burmester et al. LANCET
- Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors
- (2012) Anna Yarilina et al. ARTHRITIS AND RHEUMATISM
- Lipids and Lipoproteins and Risk of Different Vascular Events in the MRC/BHF Heart Protection Study
- (2012) Sarah Parish et al. CIRCULATION
- Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators
- (2012) Bernd Bodenmiller et al. NATURE BIOTECHNOLOGY
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- (2012) Roy Fleischmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
- (2012) Ronald F. van Vollenhoven et al. NEW ENGLAND JOURNAL OF MEDICINE
- The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon
- (2011) Sanna Rosengren et al. ANNALS OF THE RHEUMATIC DISEASES
- A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
- (2011) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
- (2011) Roy Fleischmann et al. ARTHRITIS AND RHEUMATISM
- The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells
- (2011) Keisuke Maeshima et al. ARTHRITIS AND RHEUMATISM
- Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
- (2011) Kamran Ghoreschi et al. JOURNAL OF IMMUNOLOGY
- The Pathogenesis of Rheumatoid Arthritis
- (2011) Iain B. McInnes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate
- (2011) Yoshiya Tanaka et al. ARTHRITIS CARE & RESEARCH
- Treating rheumatoid arthritis to target: recommendations of an international task force
- (2010) J. S. Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative
- (2010) Daniel Aletaha et al. ARTHRITIS AND RHEUMATISM
- Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050
- (2010) J. S. Fridman et al. JOURNAL OF IMMUNOLOGY
- The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo
- (2009) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women
- (2009) Samia Mora et al. CIRCULATION
- A quantitative analysis of kinase inhibitor selectivity
- (2008) Mazen W Karaman et al. NATURE BIOTECHNOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now